Esperion Therapeutics | ESPR - Pre Tax Profit


Esperion Therapeutics reported $63.67M in Pre-Tax Profit for its fiscal quarter ending in December of 2025.





Pre Tax Profit Change Date
AbbVie USD 4.38B 1.92B Sep/2025
Alnylam Pharmaceuticals USD 161.14M 77.83M Dec/2025
Alterity Therapeutics Limited AUD -4.74M 3.53M Dec/2024
Amarin USD -852K 7.26M Dec/2025
Amgen USD 3.92B 2.35B Sep/2025
Biogen USD 557.3M 186.7M Sep/2025
BioMarin Pharmaceutical USD -26.32M 324.19M Sep/2025
Cipla INR 11.69B 6.85B Dec/2025
CSL USD 2.61B 1.21B Dec/2025
Cytokinetics USD -183.03M 123.15M Dec/2025
Daiichi Sankyo JPY 106.73B 48.96B Dec/2025
Eli Lilly USD 7.23B 456M Sep/2025
Esperion Therapeutics USD 63.67M 95M Dec/2025
Geron USD -31.14M 12.72M Dec/2025
Grifols EUR 257.85M 190.87M Dec/2024
Halozyme Therapeutics USD 218.96M 14.02M Sep/2025
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Ionis Pharmaceuticals USD -228M 99M Dec/2025
Merck USD 6.74B 22M Sep/2025
Minerva Neurosciences USD 22.51M 30.74M Sep/2024
Moderna USD -187M 631M Sep/2025
Nektar Therapeutics USD -34.7M 2.35M Dec/2025
Pfizer USD 3.33B 290M Sep/2025
PTC Therapeutics USD -139.08M 116.01M Dec/2025
Puma Biotechnology USD 20.61M 24.76M Sep/2024
Regeneron Pharmaceuticals USD 1.76B 244.6M Sep/2025
Sanofi EUR -1.16B 5.5B Dec/2025
Sarepta Therapeutics USD -407.67M 213.63M Dec/2025
United Therapeutics USD 444M 6M Dec/2025
Vanda Pharmaceuticals USD -22.92M 16.68M Dec/2024